With respect to other pathways associated with oncogenic KRAS activity in the lung, the therapeutic targeting of PI3K has been plagued by dose‐limiting toxicities that prevent the use of high concentrations of inhibitors needed to penetrate the tumor and execute anti‐cancer activity (Castellano et al, 2013). The gene discussed is KRAS; the disease is cancer.